Gsa Capital Partners LLP Gain Therapeutics, Inc. Transaction History
Gsa Capital Partners LLP
- $1.43 Billion
- Q2 2025
A detailed history of Gsa Capital Partners LLP transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 12,756 shares of GANX stock, worth $23,088. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,756Holding current value
$23,088% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding GANX
# of Institutions
39Shares Held
4.47MCall Options Held
37.9KPut Options Held
0-
Jones Financial Companies Lllp677KShares$1.23 Million0.0% of portfolio
-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.07 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.02 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA534KShares$967,1770.0% of portfolio
-
Geode Capital Management, LLC Boston, MA290KShares$525,7360.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $21.5M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...